[ad_1]
(Photo by Mark Wilson/Getty)
Remember “Pharma Bro” Martin Shkreli? He rose to infamy in the mid-2010s for raising the price of the lifesaving drug Daraprim by 4,000% overnight — plus there was the whole securities fraud thing, that took down a Biglaw partner with him. Oh, and disrespecting Wu-Tang.
Anyway, in 2020, Shkreli was sued by New York State Attorney General Letitia James, the Federal Trade Commission, and seven individual states for that whole scheme to raise the price of a lifesaving drug thing. The trial court found Shkreli utilized monopoly power — including while he was in jail for securities fraud — in furtherance of his illegal scheme to raise the price of Daraprim and ordered Shkreli to disgorge $64.6 million in profits and banned him from the pharmaceutical industry for life. Southern District of New York judge Denise Cote wrote, “Without a lifetime ban, there is a real danger that Shkreli will engage in anticompetitive conduct within the pharmaceutical industry again.”
Harsh stuff for sure. And Shkreli appealed to the Second Circuit. There he did not find a sympathetic audience. A unanimous panel of Barrington D. Parker Jr., Myrna Pérez, and Sarah A.L. Merriam rejected his arguments and upheld the order to pay the $64.6 million and the lifetime ban from pharma.
None of that makes Shkreli a happy camper, so like many a manchild he’s taken to X, née Twitter, to complain.
Of course, like so much water off a duck’s back this will mean nothing to the Second Circuit. However, it isn’t the last a court will hear about the decision. James cited Shkreli’s industry-wide ban in support of the ban from the real estate industry her office is seeking in the civil fraud trial of Donald Trump.
Kathryn Rubino is a Senior Editor at Above the Law, host of The Jabot podcast, and co-host of Thinking Like A Lawyer. AtL tipsters are the best, so please connect with her. Feel free to email her with any tips, questions, or comments and follow her on Twitter @Kathryn1 or Mastodon @Kathryn1@mastodon.social.
[ad_2]
